BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

...Lung Therapeutics closes $36M series C Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C...
...orphan and more prevalent autoimmune diseases and orphan oncology indications. BC Staff LTI-01 LTI-03 Hansoh Pharmaceutical Group Co. Ltd. Inhibrx Inc. Lung Therapeutics Inc. Orchard...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...VP, commercial operations, corporate strategy and business development at Collegium Pharmaceutical Inc. (NASDAQ:COLL). Pulmonary company Lung Therapeutics Inc....
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...and CanBas Co. Ltd. has an XPO1 inhibitor in Phase I testing for solid tumors. Lung Therapeutics Inc....
...Cambridge, U.K. Ideaya Biosciences Inc., South San Francisco, Calif. Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Newton, Mass. Lung Therapeutics Inc....
BioCentury | Jan 26, 2018
Financial News

Bios provides BIOS Fund II update

...biopharmaceutical and medical device companies. The company has participated in venture rounds for pulmonary company Lung Therapeutics Inc....
BioCentury | Jun 9, 2017
Financial News

Lung Therapeutics raises $14.3M in series B

...On June 6, pulmonary company Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round...
...led by Bios Partners. Founding investor UT Horizon Fund also participated. Lung Therapeutics Inc. , Austin, Texas Alicia Parker Lung Therapeutics Inc....
BioCentury | Jun 7, 2017
Company News

Lung Therapeutics raises $14.3M series B round

...cardiac fibrosis, scleroderma and kidney fibrosis. Lung raised $2.8 million in its series A round. Alicia Parker Lung Therapeutics Inc....
BioCentury | Mar 23, 2017
Clinical News

LTI-01: Ph Ia/Ib started

...3 days in about 21 patients with a buildup of non-draining fluid around their lungs. Lung Therapeutics Inc....
...effusion and avoidance of surgical intervention to remove loculations Status: Phase Ia/Ib started Milestone: NA Julian Zhu LTI-01 Lung Therapeutics Inc. Plasminogen...
BioCentury | Mar 30, 2015
Emerging Company Profile

Effusion dissolution

...not have plans to study Activase in these indications, but supports investigator-sponsored trials in them. Lung Therapeutics...
...and Institutions Mentioned Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Genentech Inc., South San Francisco, Calif. Lung Therapeutics Inc....
...pleural injury in rabbits." American Journal of Physiology Lung Cellular and Molecular Physiology (2007) Sidebars Lung Therapeutics Inc....
BioCentury | Feb 5, 2015
Finance

PPPs holding steady

...Caribou Biosciences Inc. (launched) Company Lq3 Pharmaceuticals Inc. Dental U.S. Liquidia Technologies Inc. (launched) Company Lung Therapeutics Inc....
BioCentury | Jan 12, 2015
Clinical News

LTI-01 regulatory update

...FDA granted Orphan Drug designation to LTI-01 from Lung Therapeutics to treat empyema, a condition resulting from...
...pleural effusion. The single-chain urokinase plasminogen activator is in preclinical testing to treat pleural effusion. Lung Therapeutics Inc....
Items per page:
1 - 10 of 11
BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

...Lung Therapeutics closes $36M series C Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C...
...orphan and more prevalent autoimmune diseases and orphan oncology indications. BC Staff LTI-01 LTI-03 Hansoh Pharmaceutical Group Co. Ltd. Inhibrx Inc. Lung Therapeutics Inc. Orchard...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...VP, commercial operations, corporate strategy and business development at Collegium Pharmaceutical Inc. (NASDAQ:COLL). Pulmonary company Lung Therapeutics Inc....
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...and CanBas Co. Ltd. has an XPO1 inhibitor in Phase I testing for solid tumors. Lung Therapeutics Inc....
...Cambridge, U.K. Ideaya Biosciences Inc., South San Francisco, Calif. Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Newton, Mass. Lung Therapeutics Inc....
BioCentury | Jan 26, 2018
Financial News

Bios provides BIOS Fund II update

...biopharmaceutical and medical device companies. The company has participated in venture rounds for pulmonary company Lung Therapeutics Inc....
BioCentury | Jun 9, 2017
Financial News

Lung Therapeutics raises $14.3M in series B

...On June 6, pulmonary company Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round...
...led by Bios Partners. Founding investor UT Horizon Fund also participated. Lung Therapeutics Inc. , Austin, Texas Alicia Parker Lung Therapeutics Inc....
BioCentury | Jun 7, 2017
Company News

Lung Therapeutics raises $14.3M series B round

...cardiac fibrosis, scleroderma and kidney fibrosis. Lung raised $2.8 million in its series A round. Alicia Parker Lung Therapeutics Inc....
BioCentury | Mar 23, 2017
Clinical News

LTI-01: Ph Ia/Ib started

...3 days in about 21 patients with a buildup of non-draining fluid around their lungs. Lung Therapeutics Inc....
...effusion and avoidance of surgical intervention to remove loculations Status: Phase Ia/Ib started Milestone: NA Julian Zhu LTI-01 Lung Therapeutics Inc. Plasminogen...
BioCentury | Mar 30, 2015
Emerging Company Profile

Effusion dissolution

...not have plans to study Activase in these indications, but supports investigator-sponsored trials in them. Lung Therapeutics...
...and Institutions Mentioned Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Genentech Inc., South San Francisco, Calif. Lung Therapeutics Inc....
...pleural injury in rabbits." American Journal of Physiology Lung Cellular and Molecular Physiology (2007) Sidebars Lung Therapeutics Inc....
BioCentury | Feb 5, 2015
Finance

PPPs holding steady

...Caribou Biosciences Inc. (launched) Company Lq3 Pharmaceuticals Inc. Dental U.S. Liquidia Technologies Inc. (launched) Company Lung Therapeutics Inc....
BioCentury | Jan 12, 2015
Clinical News

LTI-01 regulatory update

...FDA granted Orphan Drug designation to LTI-01 from Lung Therapeutics to treat empyema, a condition resulting from...
...pleural effusion. The single-chain urokinase plasminogen activator is in preclinical testing to treat pleural effusion. Lung Therapeutics Inc....
Items per page:
1 - 10 of 11